• Home
  •  / Maze Therapeutics

Maze Therapeutics

OverviewSuggest Edit

Maze Therapeutics is translating novel genetic insights into lifesaving medicines, through an approach that integrates human genetics and functional genomics. The Company is focused on building a platform to discover and drug genetic modifiers, genes that can negate the harmful effects of other genes.

TypePrivate
Founded2018
HQRedwood City, CA, USMap
Websitemazetx.com
View Jobs

Recent NewsAll News

Latest Updates

Employees (est.) (May 2021)102
Cybersecurity ratingBMore

Key People/Management at Maze Therapeutics

Charles Homcy

Charles Homcy

Chairman of the Board
Tim Behrens

Tim Behrens

Senior Vice President, Human Genetics
Brendan Bulik-Sullivan

Brendan Bulik-Sullivan

Director
Sarah Noonberg

Sarah Noonberg

Chief Medical Officer
Jason Coloma

Jason Coloma

President, Chief Mazer, Director
Matt Brauer

Matt Brauer

Vice President, Data Science
Show more

Maze Therapeutics Office Locations

Maze Therapeutics has offices in Redwood City and South San Francisco
Redwood City, CA, US (HQ)
123 Saginaw Dr
South San Francisco, CA, US
171 Oyster Point Blvd STE 300
Show all (2)

Maze Therapeutics Financials and Metrics

Summary Metrics

Founding Date

2018

Maze Therapeutics total Funding

$191 m

Time since last funding

2 years ago

Maze Therapeutics investors

City Hill Ventures, ARCH Venture Partners, Third Rock Ventures, Foresite Capital, Casdin Capital, GV, Alexandria Venture Investments
Show all financial metrics

Maze Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

B

86/100

Learn more about our premium products
SecurityScorecard logo

Maze Therapeutics Online and Social Media Presence

Maze Therapeutics's Trends

Embed Graph

Maze Therapeutics News and Updates

October 23, 2019

City Hill Ventures funds Maze Therapeutics

Maze Therapeutics, a company focused on translating genetic insights into new medicines, has secured funding from City Hill Ventures. No financial terms were disclosed. In addition to the funding, Dr. Jonathan Lim, founder and managing partner at City Hill, has joined the Maze board of directors.

Maze Therapeutics Blogs

March 23, 2021

Maze Therapeutics Appoints Atul Dandekar as Chief Strategy Officer and Expands Board of Directors

SOUTH SAN FRANCISCO, CALIF., March 23, 2021 – Maze Therapeutics, a company translating genetic insights into new precision medicines, today announced that Atul Dandekar, a successful business leader with nearly 25 years of pharmaceutical industry experience, has joined the Company...
March 23, 2021

Maze Therapeutics Reveals Its Initial Three Lead Programs Targeting Underlying Genetic Drivers of Life-threatening Diseases

Lead Programs Advancing for the Treatment of Pompe Disease, Chronic Kidney Disease and Amyotrophic Lateral Sclerosis Maze’s COMPASS Platform Unlocked Deep Genetic Insights, Combining Human Genetic Data, Functional Genomics and Data Science to Identify Lead Candidates Additional Novel Research Progra…
March 04, 2021

Top Life Sciences Startups to Watch in 2020

  BioSpace is proud to present its NextGen Bio “Class of 2020,” a list of up-and-coming life sciences companies in North America that launched* no earlier than mid-2018. To come up with this list, BioSpace sorted companies into that age grouping, and...
March 04, 2021

Endpoints News: Maze Therapeutics Spins Out Two New Companies with Alloy and BridgeBio

The start­up has be­come the starter. Just un­der two years af­ter burst­ing on­to the scene with close to $200 mil­lion, Maze Ther­a­peu­tics is spin­ning out two new com­pa­nies, fo­cus­ing its hu­man ge­net­ics and func­tion­al ge­nomics plat­form on oph­thal­mol­o­gy and car­dio­vas­cu­lar...
March 04, 2021

Maze Allies With BridgeBio and Alloy to Create 2 Biotechs

Maze Therapeutics has partnered to create two startups focused on cardiovascular and ophthalmic diseases. The startups will benefit from Maze’s human genetics and functional genomics platform as well as the capabilities of either Alloy Therapeutics or BridgeBio Pharma. Last year,...
December 07, 2020

Maze Therapeutics and Alloy Therapeutics Form Broadwing Bio to Develop Antibody Therapies for Genetically Validated Targets in Ophthalmic Diseases

SOUTH SAN FRANCISCO, CALIF., and LEXINGTON, MASS., Dec. 7, 2020 – Maze Therapeutics, a company focused on translating genetic insights into new medicines, and Alloy Therapeutics, a company developing platforms and services to enable drug discovery, today announced the formation...
Show more

 Maze Therapeutics Frequently Asked Questions

  • When was Maze Therapeutics founded?

    Maze Therapeutics was founded in 2018.

  • Who are Maze Therapeutics key executives?

    Maze Therapeutics's key executives are Charles Homcy, Tim Behrens and Brendan Bulik-Sullivan.

  • How many employees does Maze Therapeutics have?

    Maze Therapeutics has 102 employees.

  • Who are Maze Therapeutics competitors?

    Competitors of Maze Therapeutics include GenVec, Synchronicity Pharma and GeneQuine Biotherapeutics.

  • Where is Maze Therapeutics headquarters?

    Maze Therapeutics headquarters is located at 123 Saginaw Dr, Redwood City.

  • Where are Maze Therapeutics offices?

    Maze Therapeutics has offices in Redwood City and South San Francisco.

  • How many offices does Maze Therapeutics have?

    Maze Therapeutics has 2 offices.